

Sprint Bioscience's CFO Mathias Skalmstad leaves the company

Sprint Bioscience AB (publ) announces that Mathias Skalmstad has decided to step down from his position as CFO to take on a new role at another company.

A recruitment process to find his successor will now begin. Mathias will remain at Sprint Bioscience during his three-month notice period.

"Mathias' contributions over his more than three years at Sprint Bioscience have been valuable to the company's development, both in his role as CFO and as acting CEO during 2023. I want to extend a big thank you for the time we have worked together and wish him the best in his future career," said Johan Emilsson, CEO of Sprint Bioscience.

For further information, kindly contact:

Johan Emilsson, CEO, Sprint Bioscience
Tel: +46 (8) 411 44 55
Epost: johan.emilsson@sprintbioscience.com

About Sprint Bioscience AB (publ)

Sprint Bioscience develops small molecule first-in-class drug programs with a focus on oncology. With a fragment-based drug development method, the company develops drug programs in a time- and resource-efficient manner. The programs are out-licensed to global pharmaceutical companies during the pre-clinical phase and the company has successfully entered into several license agreements. The Sprint Bioscience share is listed on the Nasdaq First North Premier Growth Market and trades under the ticker symbol SPRINT. The company is based in Stockholm with operations located in Huddinge. Further information is available on the company's website: www.sprintbioscience.com. Certified Advisor is FNCA Sweden AB, www.fnca.se.

Attachments

[Sprint Bioscience's CFO Mathias Skalmstad leaves the company](#)